Deregulation of fibroblast growth factor (FGF) signalling is observed in several types of cancer, which makes this pathway a highly promising potential therapeutic target. However, aberrant FGF receptor (FGFR) signalling can be challenging. In this Review, Babinaet al. discuss the differences between diverse mechanisms of oncogenic activation of FGFR, and the factors that determine response and resistance to FGFR targeting.
- Irina S. Babina
- Nicholas C. Turner